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ARTICLE OPEN
Glembatumumab vedotin for patients with metastatic,
gpNMB overexpressing, triple-negative breast cancer
(“METRIC”): a randomized multicenter study
Linda T. Vahdat 1,19✉, Peter Schmid2,19, Andres Forero-Torres3, Kimberly Blackwell4, Melinda L. Telli5, Michelle Melisko6,
Volker Möbus7, Javier Cortes8, Alberto J. Montero9, Cynthia Ma10, Rita Nanda11, Gail S. Wright12, Yi He13,15, Thomas Hawthorne13,
Rebecca G. Bagley13,16, Abdel-Baset Halim13,17, Christopher D. Turner13,18 and Denise A. Yardley14
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is
overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a
randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-
overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive,
GV (1.88mg/kg IV q21 days) or capecitabine (2500mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per
independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS
was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and
leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary
endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.
npj Breast Cancer            (2021) 7:57 ; https://doi.org/10.1038/s41523-021-00244-6
INTRODUCTION
It is estimated that 268,600 new cases of breast cancer and 41,760
deaths would occur in 2019 in the United States1; globally, these
numbers reach 2,088,849 new cases and 626,679 deaths2. Triple-
negative breast cancer (TNBC), which under-expresses the
estrogen and progesterone hormone receptors (ER, PR) and the
human epidermal growth factor receptor (HER2), accounts for
15–20% of all breast cancers. Effective treatment for TNBC is
limited as hormonal therapies and HER2-targeted agents are not
applicable, and no approved molecularly targeted drugs were
available until the approval of olaparib and talazoparib in 2018,
limited to patients with a germline BRCA mutation3,4, or
atezolizumab, targeting tumors that express programmed death
(PD)-L1-positive immune cells, and the recently approved
sacituzumab govitecan-hizy. Capecitabine is a standard of care
option for patients with TNBC resistant to anthracyclines and
paclitaxel, however, the benefit is modest with progression-free
survival (PFS) reported to be 1.7–2.7 months5–8.
gpNMB (glycoprotein non-metastatic B) is an internalizable
transmembrane protein overexpressed in ~40% TNBC and associated
with a poor prognosis9. Preclinical studies have implicated gpNMB in
tumor cell invasion, metastasis, and angiogenesis10–12. Glembatumu-
mab vedotin (GV) is an antibody–drug conjugate (ADC) consisting of
a fully-human gpNMB-specific IgG2 antibody coupled to the
microtubule inhibitor monomethyl auristatin E (MMAE) via a
protease-sensitive valine-citrulline peptide linker, designed to induce
cell cycle arrest and cell death by releasing MMAE after internaliza-
tion into the lysosomal compartment of gpNMB-expressing cells.
ADCs are well-established and highly active therapeutics in breast
cancer and other malignant diseases8,13–15.
The initial safety evaluation and recommended phase 2 dose of
GV were determined in a phase 1/2 study in heavily pre-treated,
advanced breast cancer (NCT# 00704158)16. In the subsequent
phase 2 “EMERGE” study (NCT# 01156753), GV demonstrated
preliminary evidence of activity in a similar patient population17.
An exploratory biomarker analysis from EMERGE also suggested
that patients with advanced TNBC overexpressing gpNMB (i.e.,
≥25% tumor epithelial cells staining positive by immunohisto-
chemistry (IHC)) were most likely to derive greater benefit from
GV, compared with standard chemotherapies. Because of the
exploratory nature of the analysis and the limited sample size of
the cohort, the METRIC study was conducted to assess in a
randomized, controlled fashion whether GV would improve PFS
compared with capecitabine for patients with gpNMB-overexpres-
sing, metastatic TNBC.
RESULTS
Population and baseline characteristics
A total of 1531 patients were screened for study eligibility (Fig. 1).
Of the 1172 (77%) patients for whom tumor tissue was provided
and adequate for gpNMB expression testing, 650 (55%) had
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tumors overexpressing gpNMB (i.e., ≥25% cells positive). Between
19 February 2014 and 21 August 2017, 327 patients were
randomized to receive GV (218) or capecitabine (109) and
constituted the intention-to-treat population. All patients sub-
mitted tissue collected in the advanced disease setting. In all, 109
(33%) of randomized patients had recent tumor biopsies for
eligibility testing while the remaining 218 (67%) patients
submitted archival tissue. Twenty-two patients, 5 in the GV arm
and 17 in the capecitabine arm, were randomized but did not
receive study treatment, owing to concern over randomization to
the control arm and failure to meet eligibility. Thus, 213 and 92
patients in the GV and capecitabine arms, respectively, were
included in the safety population. Although eligibility for
enrollment (including confirmation of measurable baseline
disease) was determined by the center, the imaging review
committee (IRC) assessment determined the measurable disease
population. A total of 179 patients in the GV arm and 100 patients
in the capecitabine arm were assessed by the IRC to have at least
one RECIST 1.1 measurable lesion at baseline and constituted the
measurable disease population.
Based on the accumulation of events, 30 November 2017 was
pre-selected as the cutoff for the primary analysis. After all data
were read and cleaned through this date, a total of 223 PFS events
had accumulated and were utilized for data analysis.
Pretreatment demographic, baseline, and disease characteristics
were well balanced between treatment groups (Tables 1 and 2),
with exception of the determination of patients with measurable
disease by IRC, as noted above. All enrolled patients were female
with a median age of 55 years. At study entry, most patients (77%)
had visceral disease and 50% had ≥3 sites of disease. All but one
patient had received taxane and 86% had prior anthracycline.
Patients had received a median of 1 (range 0–5) prior anticancer
therapies for advanced disease. Sixty percent of patients
progressed within 6 months from the end of their last cytotoxic-
containing regimen with 40% of patients having the best response
of the progressive disease.
Activity results
Median PFS by IRC was 2.9 months (95% CI: 2.8, 3.5) for the GV arm
and 2.8 months (1.6, 3.2) months for the capecitabine arm
(HR= 0.95; 95% CI: 0.71, 1.29; p= 0.7607) (Fig. 2A, Table 3). By
investigator assessment, median PFS was 2.9 months (95% CI: 2.8,
3.1) for the GV arm and 2.7 months (95% CI: 1.8, 3.4) for the
capecitabine arm (HR= 1.13; 95% CI: 0.85, 1.52; p= 0.4051). The
secondary outcomes of OS, ORR, and duration of response (DOR)
in the ITT population were similar between treatment arms.
Median OS was 8.9 (95% CI: 7.9, 10.5) months for the GV arm
and 8.7 (95% CI: 6.9, 10.8) months for the capecitabine arm (HR=
1.06; 95% CI: 0.78, 1.43; p= 0.7255) (Fig. 2B, Table 3). Additional
therapies received after study treatment and during survival
follow-up were generally well balanced between study arms
(Supplementary Table 1). Fifty-five percent of patients received
additional anticancer medications, including 29% of patients in
the GV arm who received capecitabine and ≥10% of patients in
both treatment arms who received eribulin, carboplatin, or
gemcitabine. The response rate to subsequent therapies was only
4%, consistent across study treatment arms.
ORR by IRC in the measurable disease ITT population was 16%
(95% CI: 11.1, 22.4) for the GV arm and 15% (95% CI: 8.6, 23.5) for
the capecitabine arm (Table 3). The proportion of patients with
any tumor shrinkage by IRC was 63% in the GV arm and 39% in
the capecitabine arm (Fig. 3). The median DOR was 2.8 months
(95% CI: 2.3, 5.5) for the GV arm and 4.2 months (95% CI: 2.7, 5.6)
1531 patients assessed for eligibility
1204 excluded 
697 tumor tissue inadequate for testing/gpNMB negative 
256 did not meet other eligibility criteria
77 refused to participate 
45 died during screening period 
28 enrollment closed 
94 other, not specified or categorized 
7 unknown reason 
327 randomly assigned






15 on treatment at primary analysis 
1 transitioned to compassionate use
218 assigned glembatumumab vedotin
65 alive, on study 
134 died 
14 discontinued study follow-up 
6 patient request 
6 lost to follow-up 
2 other
218 included in intention-to-treat analysis
179 included in the measurable disease analysis
213 included in the safety population
109 assigned capecitabine 
213 received 
treatment 








6 symptomatic deterioration 
10 adverse event 
6 patient decision
3 receipt of alternative anti-cancer treatments 
6 on treatment at primary analysis
11 alive, on study 
65 died 
16 discontinued study follow-up 
15 patient request 1 other
109 included in intention-to-treat analysis
100 included in the measurable disease analysis 
92 included in the safety population
Fig. 1 METRIC trial patient disposition.
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for the capecitabine arm. Outcomes of PFS, ORR, and DOR by
investigator review are presented in Supplementary Table 2.
The pre-specified subgroup analyses did not reveal any patient
subgroups with statistically significant differences in PFS and OS
between treatment arms (Figs. 4, 5, Supplementary Fig. 1);
however, a non-significant trend towards PFS benefit was
observed for patients who did not experience progression of
disease for >6 months after the last taxane therapy. Therefore, we
conducted additional post hoc analyses to examine whether the
extent of prior taxane exposure impacted outcome. For patients
with one prior line of taxane therapy, (received in any setting and
including one patient violating protocol eligibility who did not
receive any taxane), the GV and capecitabine arms, respectively
demonstrated median PFS of 3.0 months (95% CI: 2.8, 3.9) vs.
1.9 months (95% CI: 1.5, 3.1) (HR= 0.67; 95% CI: 0.47, 0.95) by IRC
and 2.9 months (95% CI: 2.8, 3.8) vs. 1.9 months (95% CI: 1.5, 2.9)
(HR= 0.79; 95% CI: 0.56, 1.11; p= 0.1806) by investigator review
(Supplementary Fig. 2). ORR was 26% vs. 18% by IRC and 30% vs.
18% by investigator review. However, no difference in OS was
observed between treatment arms in this subgroup.
Within the GV arm, early development of rash was explored to
determine whether there was any association with improved
outcome. For the subgroup of patients who developed rash in the
first treatment cycle compared with those who did not, median
PFS by IRC was 3.9 months (95% CI: 2.9, 4.2) vs. 2.8 months (95%
CI: 1.6, 4.1) (HR= 0.78; 95% CI: 0.48, 1.28; p= 0.3277), ORR by IRC
was 31% (95% CI: 21.9, 40.2) vs. 15% (95% CI: 4.4, 34.9) (p=
0.0475), and median OS was 13.4 months (95% CI: 10.1, 16.7) vs.
18.6 months (95% CI: 9.5, 19.7) (HR= 1.10; 5% CI: 0.64, 1.88; p=
0.7269). Although a significant difference in ORR was observed for
this subgroup who developed rash in the first treatment cycle of









No. % No. % No. %
Age, years
Median 55 55 55
Range 28–85 31–85 28–85
ECOG performance status
0 106 49 60 55 166 51
1 111 51 47 43 158 48
2 1 1 1 1 2 1
Unknown 0 0 1 1 1 <1
Visceral diseasea 173 79 80 73 253 77
Duration of disease since
initial diagnosis of breast
cancer, years
Median 2.5 2.3 2.4
Rangeb 0.3–30.9 0.3–35.3 0.3–35.3
Duration of metastatic
disease, years
Median 0.6 0.6 0.6
Range 0–8.0 0–3.4 0–8.0
Historic or current CNS
involvement





216 99 108 99 324 99
ER/PR < 1% 189 87 98 90 287 88
ER/PR 1–9% 28 13 11 10 39 12
gpNMB expression by IHCd
<25% 1 1 1 <1
25–49% 78 36 43 39 121 37
50–<75% 69 32 29 27 98 30
75–100% 71 33 36 33 107 33
No. of prior anticancer
regimense
Median 2 2 2
Range 1–5 1–5 1–5
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PR
progesterone receptor, HER2 human epidermal growth factor receptor 2,
gpNMB glycoprotein NMB.
aVisceral disease: tumor in lung, liver, spleen, esophagus, stomach, small
intestine, colon, rectum, omentum, peritoneum, kidney, pancreas, or
adrenal gland.
bTime from initial diagnosis of breast cancer, including patients who were not
triple-negative at the time or whose receptor status was unknown.
cTriple-negative status was unknown for two patients in the glembatumu-
mab vedotin arm and one patient in the capecitabine arm. ER/PR % positivity
was unknown for one patient in the glembatumumab vedotin arm.
dgpNMB: based on % expression in malignant epithelial cells from the last
sample before first dose of study drug. The highest expression is reported
there was ≥1 sample collected with the same date.
eIncluding hormonal therapies.









No. % No. % No. %
No. of prior cytotoxic-
containing regimens in
metastatic setting
Median 1 1 1
Rangea 0–3 0–4 0–4
No. of prior relapses in the
advanced setting
0 45 21 21 19 66 20
1 122 56 58 53 180 55
2 42 19 24 22 66 20
3 9 4 6 6 15 5
Prior anthracycline 185 85 95 87 280 86
Prior taxane
No. of prior taxane
therapies
0 0 0 1 1 1 <1
1 164 75 74 68 238 73
2 51 23 33 30 84 26
≥3 3 1 1 1 4 1
Progression-free interval
post taxaneb
≤6 months 112 51 51 47 163 50
>6 months 106 49 58 53 164 50
aProtocol eligibility required no more than two cytotoxic regimens in the
advanced setting. There was one patient in each treatment arm that did
deviate from this eligibility criteria.
bDetermined from the last taxane received.
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GV as compared with those who developed rash to capecitabine,
no differences were seen in PFS or OS for the same subgroup.
The total number of patients who had any serum samples tested
for either ADC, TA, or MMAE pharmacokinetic (PK) analysis was 207.
Post-infusion serum concentrations of ADC, TA, and MMAE are
presented in Table 4. However, it should be noted that the MMAE
concentrations are not indicative of maximum levels of exposure
because MMAE levels tend to peak between 2 and 7 days post
infusion18. No clear correlations were observed between maximum
concentrations of ADC, TA, or MMAE and best overall response.
Median cycle 1 TA levels appear higher in patients who experienced
rash in cycle 1 as compared with those who did not (P= 0.005).
There were no significant differences in maximum cycle 1
concentration of ADC, TA, and MMAE in subjects experiencing
≥grade 3 treatment-related toxicity vs. those who did not.
Seventy-eight (36%) patients in the GV arm and 43 (39%) patients
in the capecitabine arm had tumors with 25–49% of cells expressing
gpNMB, whereas 140 (64%) patients in the GV arm and 65 (60%)
patients in the capecitabine arm had tumors with ≥50–100%
expression. Subgroup analyses showed no difference in PFS, ORR,
or OS between treatment arms based on levels of gpNMB
expression.
Safety results
Toxicity is presented in Table 5. The most common adverse events
were fatigue (102 [48%]), nausea (95 [45%]), rash (95 [45%]), and
alopecia (88 [41%]) in the GV arm, and diarrhea (45 [49%]), nausea
(40 [44%]), palmar-plantar erythrodysesthesia (40 [44%]), and fatigue
(39 [42%]) in the capecitabine arm. The most common grade 3–4
adverse events were neutropenia (59 [28%]), rash (26 [12%]),
leukopenia (20 [9%]), fatigue (11 [5%]), peripheral neuropathy (10
[5%]), abdominal pain (10 [5%]), dyspnea (10 [5%]), and lymphopenia
(10 [5%]) in the GV arm, and fatigue (22 [24%]), diarrhea (12 [14%]),
palmar-plantar erythrodysesthesia (7 [8%]), constipation (5 [5%]),
stomatitis (5 [5%]), and lymphopenia (5 [5%]) in the capecitabine
arm. The most common serious adverse events were septic shock (7
[3%]), vomiting (7 [3%]), abdominal pain (6 [3%]), diarrhea (6 [3%]),
dyspnea (6 [3%]), and rash, including erythematous, generalized, and
maculopapular (5 [2%]), in the GV arm, and diarrhea (5 [5%]),
vomiting (4 [4%]), nausea (3 [3%]), and fatigue (3 [3%]) in the
capecitabine arm. Of the 199 reported deaths, the majority were
owing to progressive disease (118 [54%] of 134 in the GV arm and 55
[51%] of 65 in the capecitabine arm), 22 were due to unknown/other
cause (12 [6%] in the GV arm and 10 [9%] in the capecitabine arm),
and 4 were due to adverse events (all GV arm). A 62-year-old patient
died owing to sepsis and aspiration pneumonia considered unrelated
to study treatment 20 days after the first dose of GV. Three additional
patients, aged 32, 61, and 56, died owing to sepsis or septic shock,
after 9 days, 12 days, and 5 months of treatment, respectively. Three
of the events of fatal sepsis were preceded by treatment-related
neutropenia; two were assessed as potentially related to study
treatment.
Disease progression/symptomatic deterioration was the
primary reason for discontinuation of GV (73%) and capecita-
bine (61%). Forty-one [26%] of 305 patients discontinued
Fig. 2 Kaplan–Meier estimates of progression-free survival and overall survival. PFS by IRC assessment (A) and OS (B) for the intention-to-
treat population are shown in months. Tick marks represent censored data.
L.T. Vahdat et al.
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treatment owing to adverse events (31 [15%] of 213 in the GV
arm and 10 [11%] of 92 in the capecitabine arm). Toxicity
resulting in discontinuation of treatment for the GV arm vs. the
capecitabine arm included peripheral neuropathy (7 [3%] vs. 0),
rash (4 [2%] vs. 0), stomatitis (3 [1%] vs. 2 [2%]), sepsis (3 [1%]
vs. 1 [1%]), neutropenia (1 [1%] vs. 3 [3%]), and diarrhea (0 vs. 3
[3%]). Dose reductions owing to adverse events occurred in 59
[28%] patients in the GV arm and 36 [39%] patients in the
capecitabine arm. The most common events resulting in dose
reductions (for the GV arm vs. the capecitabine arm) included
peripheral neuropathy (17 [8%] vs. 0), palmar-plantar erythro-
dysesthesia (2 [1%] vs. 16 [17%]), rash (10 [5%] vs. 1 [1%]),
neutropenia (7 [3%] vs. 3 [3%]), peripheral neuropathy (7 [3%]
vs. 0), nausea (4 [2%] vs. 5 [5%]), fatigue (4 [2%] vs. 5 [5%]), and
diarrhea (3 [1%] vs. 13 [14%]).
DISCUSSION
ADcs have emerged as some of the most-active therapeutics in
breast cancer treatment today.19–22 The METRIC study is the first
randomized trial evaluating the efficacy of a gpNMB-targeted
therapy for metastatic gpNMB-expressing TNBC, and among the
first trials evaluating a molecularly targeted therapy for TNBC. GV
demonstrated more-frequent tumor shrinkage than capecitabine,
however, the responses were transient and of a shorter duration
than those treated with capecitabine. Furthermore, treatment with
GV did not offer an advantage over capecitabine in PFS or other
secondary endpoints. The safety profile of GV was similar to prior
published studies, however, offered no advantage in terms of
reduced toxicity over capecitabine.
The METRIC study was designed to confirm a prior exploratory
analysis that suggested the greatest benefit from GV was in
gpNMB-overexpressing TNBC, however, that was not confirmed in
this study. Furthermore, since the design and execution of this
study, 2 additional biomarker-driven studies of GV have been
conducted and reported in advanced melanoma23, and recurrent
pediatric osteosarcoma24, which demonstrate a lack of association
of response with the intensity of gpNMB expression. Therefore,
selecting patients based on the immunohistochemical expression
of gpNMB is not predictive of response to GV.
Additional possibilities as to why there was no advantage to
GV over capecitabine include TNBC molecular heterogeneity
and drug resistance to antimicrobular agents.
TNBC is a heterogeneous disease that can be classified into
distinct molecular subtypes by gene expression profiling and two
of the subtypes (30% of TNBC) are characterized from a gene
ontology perspective as enriched in Wnt and PI3K signaling
pathways. Recently, gpNMB was found to augment WNT-1-
mediated breast tumor initiation and growth by enhancing
PI3K/AKT/mTOR pathway signaling and B catenin activity25. As
not all the molecular subtypes of TNBC are enriched in those
pathways it is a possibility that the target was irrelevant for a
significant portion of the patients enrolled on the trial. In addition,
these different subtypes have distinct responses to neoadjuvant
chemotherapies with BL1 subtype exhibiting the highest pCR rate
(52%) and BL2 and LAR the lowest (0 and 10%, respectively)26.
MMAE, the payload chemotherapy for the gpNMB-expressing
antibody is an anti-microtubule agent and it is unknown if cross-
resistance exists with the taxanes. This raises the possibility that
GV activity might be TNBC subtype specific, however, this would
need to be evaluated in the future.
As study eligibility required that all patients had previously
received taxane-based therapy, the treated population may have
presented a certain degree of resistance to further therapy with
microtubule inhibitors such as MMAE. Although there were no
statistically significant findings in PFS in the predefined subgroup
analyses (demographics, disease history or baseline status, and
stratification factors) as shown in Figs. 4 and 5, there was a trend
towards longer PFS in patients who received GV and presented
with a progression-free interval >6 months vs. ≤6 months post-
taxane. Consequently, an exploratory ad hoc subgroup analysis
was performed suggesting the greatest benefit from GV was in the
subset of patients who had only one prior taxane-containing
regimen. These data support the hypothesis that GV may provide
greater clinical benefit in patients who are potentially taxane-
sensitive.
In addition, efflux pumps are a known mechanism of drug
resistance in cancer cells, mainly through multidrug resistance
protein 1 (MDR1), multidrug resistance-related protein 1
(MRP1), and breast cancer resistance protein (BCRP)27. MDR1
is a known efflux pump for MMAE28. By comparison, an ADC
delivering SN-38, the active metabolite of irinotecan, was
associated with a median PFS of 6.0 months in heavily pre-
treated TNBC29. Thus, one strategy that may improve the
activity of a gpNMB-targeted approach is to utilize a conjugated
toxin that is less susceptible to efflux pumps or combine with
agents that may overcome resistance (i.e., MDR1 inhibitors).
Other biological factors in the tumor microenvironment may
also have contributed to the short duration of response to GV.
Inaccessible cell surface gpNMB, insufficient intracellular MMAE
accumulation, or insufficient intratumoral concentration of MMAE
are possibilities. In addition, the polyclonal anti-gpNMB antibody
used for the IHC screening assay may have had different binding
affinities and/or specificities than the monoclonal antibody of GV.
Strategies for future research of GV could focus on a subset of
patients with gpNMB-overexpressing advanced TNBC who have
either previously responded to a taxane or have had minimal
exposure to a taxane-containing regimen. In addition, in light of
data suggesting that ADCs can cross the blood–brain barrier
owing to disruption of the vasculature by malignant pro-
cesses14,30,31, and the possible role of gpNMB in the develop-
ment of brain metastases32, there may be an opportunity for GV
to address the large unmet need for patients with breast cancer
brain metastases.






Median, months (95% CI) 2.9 (2.8, 3.5) 2.8 (1.6, 3.2)
OS
Median, months (95% CI) 8.9 (7.9, 10.5) 8.7 (6.9, 10.8)
Duration of OS follow-up







ORR by IRC, n (% [95% CI]) 29 (16%) 11.1, 22.4 15 (15%) 8.6, 23.5
Confirmed CR, n (%) 1 (<1%) 3 (3%)
Confirmed PR, n (%) 28 (16%) 12 (12%)
Any response*, n (%
[95% CI])
46 (26%) 19.5, 32.8 21 (21%) 13.5, 30.3
SD, n (%) 83 (46%) 27 (27%)
Data are n (%).
ITT intention-to-treat population, includes all enrolled patients, PFS
progression-free survival, IRC Independent Review Committee, OS overall
survival, ORR objective response rate per RECIST 1.1, CR complete response,
PR partial response, SD stable disease (minimum interval ≥6 weeks from
baseline), DOR duration of response.
*Any response including those not confirmed at subsequent disease
assessment.
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METHODS
Study design
METRIC was a phase 2b, open-label, randomized study conducted at
120 sites in the United States, Canada, Australia, United Kingdom, France,
Spain, Belgium, Germany, and Italy. The study was conducted at each of
the participating institutions according to the Declaration of Helsinki and
Good Clinical Practice Guidelines, after approval by local institutional/
ethics review boards. The full trial protocol can be found in the Appendix.
Participants
Eligible patients were ≥18 years of age with metastatic TNBC that
overexpressed gpNMB, defined as ≥25% tumor epithelial cells staining
positive in a tumor sample obtained in the advanced disease setting,
(advanced disease was intended to include locally advanced, metastatic, or
recurrent disease). Triple-negative status was confirmed in the advanced
setting and defined by ER and PR expression in <10% cells by IHC and
negative HER2 status defined as an IHC score of 0 or 1+, or in situ
hybridization (ISH) copy number <4.0 signals/cell, or ISH HER2/CEP17b ratio
<2.0 with average copy number <4.0 signals/cell. Patients with low ER and
PR expression, i.e., 1–9%, must have been deemed appropriate candidates
for chemotherapy by the investigator.
Patients must have received a prior taxane and, unless not clinically
indicated, anthracycline, with ≤2 lines of prior chemotherapy in the
advanced setting. Documented disease progression must have occurred
during or subsequent to the last anticancer regimen received. Patients
were required to have measurable disease for assessment by RECIST 1.1
criteria33. Patients were excluded from the study if they had progression/
recurrence of breast cancer within 3 months of completion of neoadjuvant
or adjuvant chemotherapy; had known brain metastases unless previously
treated and asymptomatic for ≥2 months; or persistent neuropathy >grade
1 at time of randomization.
All patients signed written informed consent prior to any protocol-
specific procedures.
Randomization and masking
Patients were stratified by a number of prior lines of chemotherapy for
























































Fig. 3 Maximum tumor shrinkage. Maximum percent tumor shrinkage is shown for patients with evaluable post-treatment measurements of
RECIST 1.1 target lesions. Best overall response was determined by RECIST 1.1 criteria33 by Independent Review Committee. For the
measurable disease population (including 15 patients in the glembatumumab arm and 11 patients in the capecitabine arm who are excluded
from the waterfall plot due to lack of complete post-treatment assessment of all RECIST 1.1 target lesions), the proportion of patients with any
tumor shrinkage was 113/179 (63%) in the glembatumumab vedotin arm and 39/100 (39%) in the capecitabine arm.
L.T. Vahdat et al.
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and by the progression-free interval after last taxane received (≤6 vs.
>6 months). Patients were randomly assigned (2:1) to the treatment
groups using a pre-specified randomization sequence, block size of 6, via
interactive response technology. As this was open-label, there was no
masking of trial participants or investigators. The IRC and biostatistical
team at the study sponsor were masked to treatment assignments until
after study closure.
Procedures
GV (Celldex Therapeutics, Inc., Fall River, MA) was administered every
3 weeks as a 90-minute intravenous infusion, starting dose of 1.88 mg/kg.
Dose reductions to 1.3 and 1.0 mg/kg were allowed for toxicity.
Capecitabine (Roche, Belgium and Accord, UK and India) was supplied
by Celldex to most clinical sites in the EU, whereas the remaining
institutions utilized available commercial supplies. Capecitabine was
administered per package insert recommendations, starting dose of
1250mg/m2 orally twice daily for 2 weeks followed by a 1-week rest
period. Subsequent capecitabine treatment was dictated by tolerance and
institutional practice. Study treatment continued until disease progression
or intolerance.
Safety assessments included physical examination, vital signs,
hematology, and blood chemistry at ~3-week intervals throughout
treatment; urinalysis ~6 weeks; and electrocardiogram at baseline and
end of treatment. Adverse events were graded according to NCI-CTCAE
version 4.0.
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Fig. 4 Progression-free survival by demographics and stratification factors. Progression-free survival was determined in the intention-to-
treat population, based on Independent Review Committee assessments. A forest plot for progression-free survival for GV compared with
capecitabine is shown by demographics and by study pre-specified randomization factors: number of prior lines of cytotoxic chemotherapy
for advanced disease, progression-free interval post last receipt of taxane, and prior receipt of anthracycline. The black square represents the
hazard ratio, whereas the odds ratios (95% CIs) are denoted by black lines.
 











































































































Fig. 5 Progression-free survival by baseline disease characteristics. Progression-free survival was determined in the intention-to-treat
population, based on Independent Review Committee assessments. A forest plot for progression-free survival for GV compared with
capecitabine is shown by baseline disease characteristics. The black square represents the hazard ratio while the odds ratios (95% CIs) are
denoted by black lines.
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Radiographic assessments were performed within 4 weeks prior to
treatment, every 6 weeks for 6 months, and every 9 weeks thereafter, or
until progression of disease. Tumor response and progression were
assessed according to RECIST 1.1 criteria. Local investigator assessments
guided treatment decisions, whereas study analyses were based on
retrospective IRC (Bioclinica, Princeton, NJ) assessments masked to
treatment assignments. Patients who experienced disease progression
were followed for survival until study closure.
Serum samples for PK analysis were drawn for patients who received GV
before and after every infusion. Intact ADC and total antibody (TA) were
quantified using enzyme-linked immunosorbent assays. Free MMAE was
quantified using liquid chromatography/mass spectrometry. The assay
Table 4. Post-infusion serum concentrations.
ADC (N= 12) TA (N= 163) MMAE (N= 48)
Mean ± SD (range) μg/ml Mean ± SD (range) μg/ml Mean ± SD (range) ng/ml
Cycle 1 58.6 ± 15.5 (38.8–98.3) 49.4 ± 16.5 (21.4–127.4) 1.52 ± 1.10 (0.36–5.02)
Cycle 2 56.1 ± 11.0 (45.3–85.6) 47.3 ± 15.0 (11.8–89.9) 1.40 ± 0.83 (0.042–4.26)
ADC antibody–drug conjugate, TA total antibody, MMAE monomethyl auristatin E, SD standard deviation.
Table 5. Toxicity.
Glembatumumab vedotin Capecitabine
(n= 213) (n= 92)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Any adverse event 61 (29%) 114 (54%) 32 (15%) 4 (2%) 40 (44%) 44 (48%) 8 (9%) 0
Fatigue 91 (43%) 11 (5%) 0 0 33 (36%) 6 (7%) 0 (0%) 0
Nausea 87 (41%) 7 (3%) 0 0 37 (40%) 2 (2%) 1 (1%) 0
Rash* 69 (32%) 26 (12%) 0 0 9 (10%) 1 (1%) 0 (0%) 0
Alopecia 88 (41%) 0 0 0 1 (1%) 0 0 0
Neutropenia* 25 (12%) 38 (18%) 21 (10%) 0 4 (4%) 2 (2%) 1 (1%) 0
Pruritus* 70 (33%) 9 (4%) 0 0 4 (4%) 0 0 0
Peripheral neuropathy* 67 (32%) 10 (5%) 0 0 9 (10%) 0 1 (1%) 0
Decreased appetite 63 (30%) 1 (1%) 0 0 15 (16%) 2 (2%) 0 0
Constipation 56 (26%) 6 (3%) 0 0 13 (14%) 0 (0%) 0 0
Diarrhea 52 (24%) 7 (3%) 0 0 32 (35%) 12 (13%) 1 (1%) 0
Vomiting 44 (21%) 6 (3%) 0 0 16 (17%) 3 (3%) 1 (1%) 0
Abdominal pain* 34 (16%) 10 (5%) 0 0 19 (21%) 3 (3%) 0 0
Pyrexia* 42 (20%) 1 (1%) 0 0 12 (13%) 0 0 0
Stomatitis 30 (14%) 7 (3%) 1 (1%) 0 19 (21%) 5 (5%) 0 0
Dyspnea 26 (12%) 9 (4%) 1 (1%) 0 10 (11%) 1 (1%) 0 0
Anemia* 29 (14%) 7 (3%) 0 0 7 (8%) 3 (3%) 0 0
Leukopenia* 14 (7%) 16 (8%) 4 (2%) 0 3 (3%) 0 (0%) 0 0
Hypokalemia* 22 (10%) 6 (3%) 0 0 5 (5%) 0 4 (4%) 0
Aspartate transferase increased 16 (7%) 8 (4%) 1 (1%) 0 5 (5%) 1 (1%) 0 0
Pain 16 (8%) 7 (3%) 0 0 3 (3%) 1 (1%) 0 0
Alanine aminotransferase increased 19 (9%) 4 (2%) 0 0 1 (1%) 2 (2%) 0 0
Lymphopenia* 9 (4%) 8 (4%) 2 (1%) 0 1 (1%) 5 (5%) 0 0
Dehydration 9 (4%) 8 (4%) 1 (1%) 0 6 (7%) 1 (1%) 0 0
Blood alkaline phosphatase increased 10 (5%) 8 (4%) 0 0 2 (2%) 0 0 0
Hypophosphatemia* 8 (4%) 6 (3%) 1 (1%) 0 2 (2%) 2 (2%) 1 (1%) 0
Palmar-plantar erythrodysesthesia syndrome 9 (4%) 2 (1%) 0 0 33 (36%) 7 (8%) 0 0
Sepsis syndrome* 0 0 3 (1%) 4 (2%) 0 0 1 (1%) 0
Pulmonary embolism 0 2 (1%) 1 (1%) 0 0 4 (4%) 0 0
Data are presented for the safety population (all patients who received at least one dose of study treatment). Table shows all grade 1–2 events occurring in
≥20% of patients in either group and any grade 3–5 event occurring in ≥6 patients overall. Four patients died due to adverse events, all on the
glembatumumab vedotin arm. Overall, 199 deaths were reported, 173 (87%) were owing to progressive disease (118 of the 134 reported deaths in the
glembatumumab vedotin arm and 55 of the 65 reported deaths in the capecitabine arm), 22 were owing to unknown/other cause (12 in the glembatumumab
vedotin arm and 10 in the capecitabine arm), and 4 due to adverse event (all on the glembatumumab vedotin arm).
*AE terms that were synonymous were combined.
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sensitivities were 0.32 μg/mL, 0.50 μg/mL, and 0.05 ng/ml for ADC, TA, and
free MMAE, respectively. Peripheral blood mononuclear cell samples were
collected from a subset of centers in the US, prior to GV dosing. The analysis
included the examination of GPNMB expression on myeloid suppressor cells.
Prospective analysis of gpNMB expression was performed by IHC at a
central laboratory (Neogenomics, Aliso Viejo, CA) using tumor tissue from the
advanced disease setting, either archived or obtained at baseline. Samples on
3–5 micron slides were deparaffinized, rehydrated, and pre-treated using
Envision FLEX target retrieval solution (Agilent, Santa Clara, CA). After proper
washing, slides were incubated with the goat anti-human gpNMB antibody
(R&D Systems, Minneapolis, MN). Visualization was achieved using horseradish
peroxidase-labeled rabbit anti-goat (Invitrogen, Carlsbad, CA) and DAB+
chromogen (Agilent). A duplicate slide from each sample was processed
similarly but replaced the goat anti-gpNMB antibody with normal goat IgG
(R&D Systems) to serve as an isotypic control. After slides were counterstained
with hematoxylin, gpNMB staining was scored by two pathologists, recording
the percentage of malignant epithelial cells staining positive. The disparity in
results between the two pathologists influencing a patient’s eligibility status
was adjudicated by the two pathologists under a multi-head microscope or by
a third pathologist.
Outcomes
The primary study objective was to demonstrate that GV improves PFS
(defined as the time from the date of randomization to documented
disease progression, or death owing to any cause, whichever is earlier)
as compared with capecitabine. PFS events were determined retro-
spectively in a masked fashion by the central IRC according to RECIST
1.1 criteria. Secondary study objectives included the effect of GV as
compared with capecitabine on objective response rate (ORR; the
proportion of patients among those with measurable disease at
baseline achieving a confirmed complete response (CR) or partial
response (PR) per RECIST 1.1 criteria), DOR (the number of months from
the start date of PR or CR [whichever is recorded first] to the first date
that PD or death is documented]), and overall survival, as well as to
further characterize the safety, and obtain PK parameters and explore
the relationships between exposure and safety and activity parameters.
Activity analyses were performed according to IRC assessments.
Statistical considerations
For the purpose of the study’s sample size calculation, it was hypothesized
that median PFS would be 4.0 months for patients with metastatic,
gpNMB-expressing TNBC treated with capecitabine alone, and GV would
increase median PFS in such patients by 2.25 months (i.e., from 4.0 to
6.25 months). Thus, 203 PFS events (total of two arms) were calculated to
provide 85% power to detect a hypothesized hazard ratio of 0.64 with two-
sided type I error 0.05.
The primary analysis of PFS was performed for the intention-to-treat
population, which consisted of all randomly assigned patients. Patients
who initiated alternate anticancer therapy in absence of documented
progression were censored at the latest disease assessment prior to
initiation of such therapy. Patients who were last known to be alive and
progression-free were censored at the latest disease assessment. PFS was
summarized using the Kaplan–Meier method and presented by the
treatment group. The primary inferential comparison of this endpoint used
the stratified log-rank test stratified by the actual stratification factors
corrected in the clinical database after randomization. Estimation of the
hazard ratio for treatment and its corresponding 95% confidence interval
(CI) was determined using a stratified Cox proportional hazards model with
the same stratification factors (SAS version 9.4).
The secondary endpoints of ORR and DOR were based on the
measurable disease population, which included patients with at least
one measurable lesion on baseline evaluation. Exact 95% CI of ORR was
calculated by treatment arm using the Clopper–Pearson method.
Inferential comparisons of the observed ORRs were made using the
Cochran–Mantel Haenszel chi-square test, stratified by the randomization
stratification factors. DOR was estimated using the Kaplan–Meier method.
To determine whether there was any association between maximum serum
concentrations and clinical activity or toxicity of GV, analyses were performed
with peak serum concentrations during cycle 1 for each analyte vs. best
overall response per RECIST 1.1 (Kruskal–Wallis, one-way analysis of variance)
or ≥grade 3 CTCAE treatment-related adverse events occurring in cycle 1
(Mann–Whitney test).
Subgroup analyses were planned according to baseline characteristics
including the randomization stratification factors, demographics, gpNMB
and ER/PR expression levels, extent of disease, performance status, and
geographical region. As early development of rash was associated with
improved outcome in prior studies of GV16,17, an additional pre-planned
subgroup analysis examined outcomes dependent on the development of
treatment-related rash during the first treatment cycle. A post hoc
exploratory analysis investigating outcomes by the number of lines of prior
taxane-containing regimens was also performed.
Safety analyses included all patients who received at least one dose of
study treatment. An independent data monitoring committee comprised
of two physicians and one biostatistician reviewed cumulative safety data
approximately every 6 months throughout study conduct. SAS version
9.4 was used for all statistical analyses. The trial is registered with
ClinicalTrials.gov (NCT01997333).
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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